Novavax (NVAX) was asked by the US Food and Drug Administration to run an additional randomized clinical trial on its COVID-19 vaccine, The Wall Street Journal reported Friday, citing people familiar with the matter.
That may cost the company tens of millions of dollars, vaccine experts said, according to the report.
The vaccine had showed 90% efficacy in a 30,000-person, placebo-controlled trial, the report said.
The FDA request allows the company to negotiate for a smaller, less expensive study, the report said, citing a person familiar with the matter.
The Department of Health and Human Services and Novavax didn't immediately respond to requests for comment from MT Newswires.
Novavax shares fell 1.4% in after-hours trading after dropping 5.7% in the regular session.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。